HopeStage
Back to all studies
CompletedNCT02023606

How the Body Processes SPN-810M in Healthy Male Volunteers

About this titleRead the official source — NCT02023606
Medication studyAges 30–55United KingdomADHD
The study in practice

Understand this study

Who was this study for?

Listed age limits: 30 years to 55 years.

Listed locations
RuddingtonSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateNovember 2013
Recruitment status
Completed
Enrollment listed in the registry
7
Sponsor
Supernus Pharmaceuticals, Inc.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United Kingdom
Age range
From 30 Years to 55 Years
Official registry ID
NCT02023606
Official title
Show the full official title

An Open-Label, Single-Dose, Mass-Balance Study to Assess the Absorption, Metabolism, and Excretion (AME) of [14C] Labeled SPN-810M in Healthy Adult Male Volunteers

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Ruddington

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Supernus Pharmaceuticals, Inc., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including SPN-810M.

Who was this study for?

Listed age limits: 30 years to 55 years.

Want to explore more studies?

Explore studies